BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 19723895)

  • 1. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease.
    Wang J; Chen J; Chang P; LeBlanc A; Li D; Abbruzzesse JL; Frazier ML; Killary AM; Sen S
    Cancer Prev Res (Phila); 2009 Sep; 2(9):807-13. PubMed ID: 19723895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
    Dittmar RL; Liu S; Tai MC; Rajapakshe K; Huang Y; Longton G; DeCapite C; Hurd MW; Paris PL; Kirkwood KS; Coarfa C; Maitra A; Brand RE; Killary AM; Sen S
    Cancer Prev Res (Phila); 2021 Jul; 14(7):729-740. PubMed ID: 33893071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.
    Karasek P; Gablo N; Hlavsa J; Kiss I; Vychytilova-Faltejskova P; Hermanova M; Kala Z; Slaby O; Prochazka V
    Cancer Genomics Proteomics; 2018; 15(4):321-327. PubMed ID: 29976637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.
    Alemar B; Izetti P; Gregório C; Macedo GS; Castro MA; Osvaldt AB; Matte U; Ashton-Prolla P
    Pancreas; 2016 Jan; 45(1):84-92. PubMed ID: 26262588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively.
    Yu Q; Xu C; Yuan W; Wang C; Zhao P; Chen L; Ma J
    Biomed Res Int; 2017; 2017():6495867. PubMed ID: 28466015
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis.
    Zhou X; Lu Z; Wang T; Huang Z; Zhu W; Miao Y
    Gene; 2018 Oct; 673():181-193. PubMed ID: 29913239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A migration signature and plasma biomarker panel for pancreatic adenocarcinoma.
    Balasenthil S; Chen N; Lott ST; Chen J; Carter J; Grizzle WE; Frazier ML; Sen S; Killary AM
    Cancer Prev Res (Phila); 2011 Jan; 4(1):137-49. PubMed ID: 21071578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.
    Akamatsu M; Makino N; Ikeda Y; Matsuda A; Ito M; Kakizaki Y; Saito Y; Ishizawa T; Kobayashi T; Furukawa T; Ueno Y
    PLoS One; 2016; 11(7):e0158669. PubMed ID: 27380024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma.
    Zhang J; Zhao CY; Zhang SH; Yu DH; Chen Y; Liu QH; Shi M; Ni CR; Zhu MH
    Oncol Rep; 2014 Mar; 31(3):1157-64. PubMed ID: 24398877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma.
    Que R; Ding G; Chen J; Cao L
    World J Surg Oncol; 2013 Sep; 11():219. PubMed ID: 24007214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
    Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
    J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
    Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
    Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Permuth-Wey J; Chen DT; Fulp WJ; Yoder SJ; Zhang Y; Georgeades C; Husain K; Centeno BA; Magliocco AM; Coppola D; Malafa M
    Cancer Prev Res (Phila); 2015 Sep; 8(9):826-34. PubMed ID: 26314797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma.
    Liu Q; Chen J; Wang J; Amos C; Killary AM; Sen S; Wei C; Frazier ML
    Mol Carcinog; 2014 Sep; 53(9):711-21. PubMed ID: 23661430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
    Meijer LL; Garajová I; Caparello C; Le Large TYS; Frampton AE; Vasile E; Funel N; Kazemier G; Giovannetti E
    Ann Surg; 2020 Jun; 271(6):1137-1147. PubMed ID: 30394883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study.
    Duell EJ; Lujan-Barroso L; Sala N; Deitz McElyea S; Overvad K; Tjonneland A; Olsen A; Weiderpass E; Busund LT; Moi L; Muller D; Vineis P; Aune D; Matullo G; Naccarati A; Panico S; Tagliabue G; Tumino R; Palli D; Kaaks R; Katzke VA; Boeing H; Bueno-de-Mesquita HBA; Peeters PH; Trichopoulou A; Lagiou P; Kotanidou A; Travis RC; Wareham N; Khaw KT; Ramon Quiros J; Rodríguez-Barranco M; Dorronsoro M; Chirlaque MD; Ardanaz E; Severi G; Boutron-Ruault MC; Rebours V; Brennan P; Gunter M; Scelo G; Cote G; Sherman S; Korc M
    Int J Cancer; 2017 Sep; 141(5):905-915. PubMed ID: 28542740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosome-encapsulated microRNA-4525, microRNA-451a and microRNA-21 in portal vein blood is a high-sensitive liquid biomarker for the selection of high-risk pancreatic ductal adenocarcinoma patients.
    Kawamura S; Iinuma H; Wada K; Takahashi K; Minezaki S; Kainuma M; Shibuya M; Miura F; Sano K
    J Hepatobiliary Pancreat Sci; 2019 Feb; 26(2):63-72. PubMed ID: 30561106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.
    Kandimalla R; Shimura T; Mallik S; Sonohara F; Tsai S; Evans DB; Kim SC; Baba H; Kodera Y; Von Hoff D; Chen X; Goel A
    Ann Surg; 2022 Jan; 275(1):e229-e237. PubMed ID: 32398486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma.
    Zhao C; Zhang J; Zhang S; Yu D; Chen Y; Liu Q; Shi M; Ni C; Zhu M
    Oncol Rep; 2013 Jul; 30(1):276-84. PubMed ID: 23612862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.